Centers | ||
|
|
|
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | EU-OPENSCREEN | Drug Discovery Unit |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The Drug Discovery Unit (DDU) is a fully integrated drug discovery group established to translate world-class biology research into novel drug targets and candidate drugs. Housed within purpose built facilities at the University of Dundee, the DDU... Read more |
Partnerships |
Events |
Jobs |
Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Pharma and Academia Consortium Partner to Develop New Drugs in EuropeA consortium of academic institutes from Germany, Britain, Netherlands and Denmark partner with a group of leading pharmaceutical companies which include AstraZeneca, Sanofi, Bayer, UCB , Lundbeck , Merck KGaA, and Janssen which is a JNJ... View all |
No EVENTS for listing |
No Job Posts |
